 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...109110111112113114115116117118119...858859» |
- | Blincyto (blinatumomab) / Astellas, Amgen
New P4 trial, Real-world evidence, Real-world: A real-world study of the use of blinatumomab bridging maintenance therapy after chemotherapy for B-cell acute lymphoblastic leukemia in children with intermediate risk (EUDRACT) - Dec 5, 2023
P4, N=628, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
.
- | Repatha (evolocumab) / Amgen, Astellas
New P4 trial: Evolocumab in the Cath Lab for Lipoprotein (a) Lowing in Patients with Acute Myocardial Infarction (EVOLUTION) - A Randomized, Open-label, Blank-controlled, Multicenter Study (EUDRACT) - Dec 5, 2023
P4, N=450, Not yet recruiting, Sponsor: The First Affiliated Hospital of Ningbo University; The First Affiliated Hospital of Ningbo University
. .
- | Blincyto (blinatumomab) / Astellas, Amgen
New P4 trial, Minimal residual disease: Efficacy and safety of one cycle Blinatumomab treatment in adult patients with MRD-positive or relapsed and refractory acute B acute lymphoblastic leukemia (EUDRACT) - Dec 5, 2023
P4, N=26, Not yet recruiting, Sponsor: Shenzhen Second People's Hospital; Shenzhen Second People's Hospital
. .
- | Stivarga (regorafenib) / Bayer
New P3 trial, Metastases: Hepatic artery infusion chemotherapy plus Regorafenib compared with Regorafenib alone in second-line therapy for advanced hepatocellular carcinoma: a randomized controlled trial (EUDRACT) - Dec 5, 2023
P3, N=294, Recruiting, Sponsor: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Cancer Center/Cancer Hospital
. .
- | Venclexta (venetoclax) / Roche, AbbVie, Ibrance (palbociclib) / Pfizer
New P1/2 trial, Combination therapy: A single-arm, open, multicenter clinical study of Palbociclib in combination with Venetoclax and Azacitidine regimen (VAP regimen) for the treatment of NUP98-R positive childhood acute myeloid leukemia (EUDRACT) - Dec 5, 2023
P1/2, N=54, Recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
. .
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Dec 5, 2023
P=N/A, N=757, Active, not recruiting, Sponsor: Takeda
. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date, Metastases: Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib (clinicaltrials.gov) - Dec 5, 2023
P2, N=25, Suspended, Sponsor: Wake Forest University Health Sciences
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
- || Retrospective data, Review, Journal: Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. (Pubmed Central) - Dec 5, 2023
Overall work productivity improved at Weeks 12-16 to a greater extent for patients who received b/tsDMARDs than placebo. Work productivity loss was associated with a substantial cost burden, which was reduced with improvements in impairment.
- ||||| Leqvio (inclisiran) / Novartis
Enrollment change, Adverse events: SIRIUS: In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease (clinicaltrials.gov) - Dec 5, 2023
P=N/A, N=204691, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Work productivity loss was associated with a substantial cost burden, which was reduced with improvements in impairment. N=54724 --> 204691
- ||| temozolomide/perillyl alcohol conjugate (NEU001) / NeOnc Technologies, NeuCen BioMed
Enrollment open, IO biomarker: Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (clinicaltrials.gov) - Dec 5, 2023
P1/2, N=134, Recruiting, Sponsor: Neonc Technologies, Inc.
N=54724 --> 204691 Not yet recruiting --> Recruiting
- ||| zeluvalimab (AMG 404) / Amgen
Trial completion, Metastases: AMG 404 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2023
P1, N=171, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| vistusertib (AZD2014) / AstraZeneca
Trial completion, Phase classification, Metastases: PASTOR: Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (clinicaltrials.gov) - Dec 4, 2023
P1, N=54, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P1/2 --> P1
- zetomipzomib (KZR-616) / Kezar
Phase classification: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) (clinicaltrials.gov) - Dec 4, 2023
P2, N=24, Recruiting, Sponsor: Kezar Life Sciences, Inc.
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 Phase classification: P2a --> P2
- | Prolia (denosumab) / Amgen
Enrollment open, Trial completion date, Trial primary completion date: EURODEC: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) (clinicaltrials.gov) - Dec 4, 2023
P=N/A, N=125, Recruiting, Sponsor: 424 General Military Hospital
Phase classification: P2a --> P2 Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Jun 2025 --> Nov 2026
- | ivabradine / Generic mfg.
Journal: A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family. (Pubmed Central) - Dec 4, 2023
Conversely, it did not modify the channel sensitivity for cAMP and ivabradine or the level of expression at the membrane...In computer simulations, the p.V240M gain-of-function variant increases I and beating rate and thus explains the IST of the carriers. The results demonstrate the importance of the unique HCN domain in HCN4, which stabilizes the channels in the closed state.
- || Aphexda (motixafortide) / BioLineRx, Gloria Pharma
Review, Journal: Motixafortide: First Approval. (Pubmed Central) - Dec 4, 2023
Clinical development is ongoing for the mobilization of CD34 HSCs for gene therapy in patients with sickle cell disease. This article summarizes the milestones in the development of motixafortide leading to this first approval.
- ||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
P3 data, Journal, HEOR: Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. (Pubmed Central) - Dec 4, 2023
P3
CMF had worse QOL effects than did capecitabine, which were persistent for 24 months. The favourable capecitabine QOL compared with CMF supports its use as an adjuvant option after neoadjuvant chemotherapy in patients with triple-negative breast cancer.
- || Review, Journal: IgG4-related disease: A proteiform pathology with frequent chest manifestations (Pubmed Central) - Dec 4, 2023
The favourable capecitabine QOL compared with CMF supports its use as an adjuvant option after neoadjuvant chemotherapy in patients with triple-negative breast cancer. Substantial progress has been made over recent years in understanding IgG4-RD pathophysiology, and personalized patient care seems to be an achievable medium-term goal.
- || Lumakras (sotorasib) / Amgen
P1 data, Journal: First-in-Humans PET Imaging of KRAS Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [F]PFPMD. (Pubmed Central) - Dec 4, 2023
Substantial progress has been made over recent years in understanding IgG4-RD pathophysiology, and personalized patient care seems to be an achievable medium-term goal. [F]PFPMD was synthesized on the basis of AMG510 (sotorasib) by attaching a polyethylene glycol chain to the quinazolinone structure...The accumulation of [F]PFPMD in KRAS mutation tumors was significantly higher than that in non-KRAS mutation tumors (SUV: 3.73?
- | camizestrant (AZD9833) / AstraZeneca, Undisclosed CDK4/6 inhibitor / CS Group
Journal: The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. (Pubmed Central) - Dec 4, 2023
Evaluation of camizestrant in combination with CDK4/6i (palbociclib or abemaciclib) in CDK4/6-naive and -resistant models, as well as in combination with PI3K?i (alpelisib), mTORi (everolimus), or AKTi (capivasertib), indicated that camizestrant was active with CDK4/6i or PI3K/AKT/mTORi and that antitumor activity was further increased by the triple combination...The response was observed independently of PI3K pathway mutation status. Overall, camizestrant shows strong and broad anti-tumor activity in ER+ breast cancer as a monotherapy and when combined with CDK4/6i and PI3K/AKT/mTORi.
- | padnarsertib (KPT-9274) / Karyopharm
Preclinical, Journal: Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. (Pubmed Central) - Dec 4, 2023
Moreover, the combination of KPT9274 and sotorasib enhances survival. In conclusion, this is the first study to demonstrate that KRASG12C inhibitors can synergize with the PAK4 inhibitor KPT9274 and combining KRASG12C inhibitors with KPT9274 can lead to remarkably enhanced antitumor activity and survival benefits, providing a novel combination therapy for cancer patients who do not respond or develop resistance to KRASG12C inhibitor treatment.
- | Journal, PARP Biomarker: Qing Yan Li Ge Tang Induces Apoptosis in Human OEC-M1 Oral Cancer Cells. (Pubmed Central) - Dec 4, 2023
Moreover, only Bay11-7082, the NF-?B inhibitor, could suppress QYLGT-induced the release of cytokeratin 18 fragments from OEC-M1 cells. QYLGT induced apoptosis in OEC-M1 cells via the NF-?B pathway.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Buds of new bone formation within the femoral head of hip fracture patients coincide with zones of low osteocyte sclerostin. (Pubmed Central) - Dec 4, 2023
Romosozumab treatment reduces the rate of hip fractures and increases hip bone density, increasing bone formation by inhibiting sclerostin protein...FMiS density correlated with greater amount, thickness, number and connectivity of trabeculae (bone volume BV/TV, r?=?0.65, p?<?0.0001; bone surface BS/TV, r?=?0.47, p?<?0.01; trabecular thickness Tb.Th, r?=?0.55, p?<?0.001; trabecular number Tb.N, r?=?0.47, p?<?0.01; and connectivity density Conn.D, r?=?0.40, p?<?0.05) and lower trabecular separation (Tb.Sp, r?=?-0.56, p?<?0.001). These results demonstrate modeling-based bone formation in femoral trabeculae from patients with hip fracture as a potential therapeutic target to enhance bone structure.
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Clinical, Journal: Second messenger signaling bypasses CGRP receptor blockade to provoke migraine attacks in humans. (Pubmed Central) - Dec 4, 2023
These findings provide clinical evidence that cAMP-evoked migraine attacks do not require CGRP receptor activation. This discovery opens up new possibilities for the development of mechanism-based drugs for the treatment of migraine.
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Effect of treatment regimen of the rheumatoid arthritis patients on the risk of coronavirus disease 2019 by modulating the inflammatory mediators. (Pubmed Central) - Dec 4, 2023
It seems that Etanercept therapy in RA cases might increase proneness of the COVID-19 risk in these cases. The mechanism of this increased risk may stem from suppressing a protective immunity state in the RA cases.
- | Journal: The predictors of paradoxical reactions especially psoriasis with biologic therapy from the TReasure database: a 5-year follow-up study. (Pubmed Central) - Dec 4, 2023
The mechanism of this increased risk may stem from suppressing a protective immunity state in the RA cases. Contrary to expectations based on earlier research suggesting that paradoxical reactions develop with the class effect of biological agents, the response of patients who were shifted to another TNFi was favourable.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Follow-up imaging of SAPHO syndrome treated with denosumab. (Pubmed Central) - Dec 4, 2023
Contrary to expectations based on earlier research suggesting that paradoxical reactions develop with the class effect of biological agents, the response of patients who were shifted to another TNFi was favourable. No abstract available
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Analysis of the evolocumab (Repatha (Pubmed Central) - Dec 4, 2023
The overall adherence found was higher than 70%; similar to findings reported in other real-life studies with iPCSK9. However, the reasons for low compliance were different, highlighting the high number of administrative and medical reasons for suspension or abandonment of treatment with evolocumab.
- ||| zoledronic acid / Generic mfg.
Journal, Adverse events: Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database. (Pubmed Central) - Dec 4, 2023
In a real-life setting, our data confirm that zoledronate-associated BRONJ in osteoporosis is scarce, seeming slightly more common compared with oral bisphosphonates. We also raise awareness of dental care guidelines and greater vigilance when using bisphosphonates in patients with previous exposure to denosumab.
- || Review, Journal: Intra-articular injections of biological disease-modifying anti-rheumatic drugs in inflammatory arthropathies: an up-to-date narrative review. (Pubmed Central) - Dec 4, 2023
The IA use of bDMARDs seems to be weakly effective in the management of resistant synovitis and not superior to GCs injections. The treatment's main limit appears to be the poor persistence of the compound in the joint.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study. (Pubmed Central) - Dec 4, 2023
P=N/A
The probability of achieving the 2019 ESC/EAS LDL-C goals would improve with combination therapy and also with a lower LDL-C threshold when starting evolocumab. Persistence to evolocumab remained high during follow-up, with a very low percentage of discontinuation (5% at 12 months; 7% at 30 months).
- | Journal: Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database. (Pubmed Central) - Dec 4, 2023
The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice.
- ||||||| Stivarga (regorafenib) / Bayer
Trial completion, Real-world evidence, Real-world, Metastases: COLONGER: An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States (clinicaltrials.gov) - Dec 4, 2023
P=N/A, N=2448, Completed, Sponsor: Bayer
This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice. Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen
New P3 trial: Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes (clinicaltrials.gov) - Dec 3, 2023
P3, N=86, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
Active, not recruiting --> Completed .
- | Ibrance (palbociclib) / Pfizer
Journal: Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer. (Pubmed Central) - Dec 3, 2023
We demonstrated a novel PEG10-associated mechanism of CDK4/6 inhibitor resistance. We propose PEG10 as a promising therapeutic target for overcoming PEG10-associated resistance to CDK4/6 inhibitors.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Effects of denosumab on bone mineral density around proximal femoral prosthesis after total hip replacement in postmenopausal osteoporotic patients (Pubmed Central) - Dec 2, 2023
We propose PEG10 as a promising therapeutic target for overcoming PEG10-associated resistance to CDK4/6 inhibitors. After THA in postmenopausal patients with osteoporotic femoral neck fracture, Desuzumab can reduce the loss of BMD around the proximal femoral prosthesis and effectively inhibit bone resorption.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document. (Pubmed Central) - Dec 2, 2023
Careful multidisciplinary planning is required to define the goals of treatment and expert oversight needed to manage the risk of mineral abnormalities. Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimise risks.
- | ivabradine / Generic mfg.
Journal: Relationship between cardiac output, heart rate and microcirculation in patients with multiorgan dysfunction syndrome (Pubmed Central) - Dec 1, 2023
Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimise risks. The results indicate that in critically ill patients, depending on the genesis of the MODS, there are different relationships between HF or CO values, on the one hand, and the parameters of the microcirculation, on the other.
- ||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
P3 data, Journal: Efficacy of Tezepelumab in Patients With Evidence of Severe Allergic Asthma: Results From the Phase 3 NAVIGATOR Study. (Pubmed Central) - Dec 1, 2023
The results indicate that in critically ill patients, depending on the genesis of the MODS, there are different relationships between HF or CO values, on the one hand, and the parameters of the microcirculation, on the other. No abstract available
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Current indications for denosumab in benign bone tumours. (Pubmed Central) - Dec 1, 2023
Data are derived, however, mostly from case reports and case series. Large prospective clinical trials are needed to evaluate the role and also the side effects of denosumab in the treatment of these rare diseases.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Nivestym (filgrastim-aafi) / Pfizer
Journal: Validation of Nivestym compared to Neupogen: An NMDP analysis. (Pubmed Central) - Dec 1, 2023
Large prospective clinical trials are needed to evaluate the role and also the side effects of denosumab in the treatment of these rare diseases. No abstract available
- | Tepezza (teprotumumab) / Roche, Amgen
Journal: The effect of acromegaly on thyroid disease. (Pubmed Central) - Dec 1, 2023
Recent studies have reported that the IGF-1 receptor (IGF-1R) plays an important role in the pathogenesis of TAO, and the IGF-1R inhibitor teprotumumab involves significantly improved disease endpoints in patients with active TAO. Thyroid-stimulating hormone (TSH) receptor (TSHR) and IGF-1R co-immunoprecipitate in orbital and thyroid tissues to form a functional complex; thus, combined therapy targeting TSHR and IGF-1R may be more effective than single therapy.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy. (Pubmed Central) - Dec 1, 2023
Overall, findings seem to indicate a favorable tolerability and effectiveness profile. Further studies are warranted to better establish the long-term comparative effectiveness, safety, and cost effectiveness of anti-CGRP mAbs compared to other preventive medications.
- | Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Trial completion date, Metastases: Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 1, 2023
P1, N=24, Active, not recruiting, Sponsor: Kathryn Gold
Further studies are warranted to better establish the long-term comparative effectiveness, safety, and cost effectiveness of anti-CGRP mAbs compared to other preventive medications. Trial completion date: Jul 2023 --> Dec 2024
- | astegolimab (RG 6149) / Amgen, Roche
Phase classification: A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Dec 1, 2023
P2, N=1440, Recruiting, Sponsor: Genentech, Inc.
Trial completion date: Jul 2023 --> Dec 2024 Phase classification: P2b --> P2
- |||| Trial completion date, Trial primary completion date: GBM AGILE: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov) - Dec 1, 2023
P2/3, N=1030, Recruiting, Sponsor: Global Coalition for Adaptive Research
Phase classification: P2b --> P2 .
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Journal: Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation. (Pubmed Central) - Nov 30, 2023
. No abstract available
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Nov 30, 2023
P1/2, N=1143, Recruiting, Sponsor: Amgen
No abstract available Trial primary completion date: Jun 2026 --> Sep 2026
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Journal, Compliance: Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom. (Pubmed Central) - Nov 30, 2023
Trial primary completion date: Jun 2026 --> Sep 2026 This analysis indicates that lifetime costs of KF in NC can be reduced through improved treatment compliance with oral cysteamine.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, HEOR: Budget impact of increasing uptake of denosumab for the treatment of postmenopausal osteoporosis in Malaysia. (Pubmed Central) - Nov 30, 2023
From the perspective of a Malaysian MOH healthcare provider, moderately increasing uptake of denosumab would have a minimal additional budget impact, partially offset by savings in fracture treatment costs. Increasing the use of denosumab appears affordable to reduce the economic burden of osteoporosis in Malaysia.